Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo poor-risk acute myelogenous leukemia (AML).

Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have reached this milestone in the pivotal Phase II trial of our lead anticancer agent. We will now proceed to analyze the data and, if warranted, prepare a New Drug Application for submission to the U.S. Food and Drug Administration in 2008." He added, "We continue to plan on the release of preliminary data from this trial at the American Society of Hematology (ASH) Meeting in December."

The pivotal Phase II trial, initiated in May 2006, is evaluating Cloretazine(R) (VNP40101M) as a single agent in previously untreated AML patients over the age of 60 with de novo poor-risk AML. Patients are eligible for this trial if they are at least 60 years of age with de novo AML and have one of the following additional risk factors: (i) unfavorable cytogenetics; (ii) an ECOG performance status of 2 or greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 with de novo AML who do not have favorable cytogenetics are also eligible.

The primary endpoint for this trial is the complete response rate (including complete remission (CR) and complete remission with incomplete platelet recovery (CRp)). Secondary endpoints include overall survival, disease-free survival and progression-free survival.

The trial ha
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 According to a new ... (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), Lab ... VT, WPW) - Global Forecasts to 2019 ", published by ... around ~$4.73 Billion by 2019 with a CAGR of ... Browse   90   ma ...
(Date:3/27/2015)... DALLAS , March 27, 2015   ... global leader in biosimilars and the world,s leading ... two studies that support an evaluation of biosimilarity ... U.S. Food and Drug Administration (FDA) conditionally approved ... Amgen,s EPOGEN™ (epoetin alfa). These study data were ...
(Date:3/27/2015)... RnRMarketResearch.com adds "Visceral Pain ... report of 52 pages with latest updates, data ... The report "Visceral Pain - Pipeline Review, H1 ... for Visceral Pain, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), ... that it has received approval for a key patent ... "Methods and Compositions for Oral Administration of Exenatide," covers ... portfolio now consists of three issued patents and 34 ...
... Diagnostics, Inc., a molecular diagnostics company, today announced it ... a meeting sponsor at the upcoming ISPD 16th International ... Fla. (Logo: http://photos.prnewswire.com/prnh/20120326/NY75864LOGO ) ... titled, "Analysis of Maternal Age, Gestational Age and Aneuploidy ...
Cached Medicine Technology:Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand 2Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand 3Ariosa Diagnostics to Present and Exhibit at the 16th International Conference on Prenatal Diagnosis and Therapy 2
(Date:3/27/2015)... Ticket Down is a reputable source of authentic Garth ... on Friday, May 8th and Saturday, May 9th. There ... in Omaha as Garth has done in other markets as ... Tour is continuing its run throughout the United States this ... Yearwood will bring their act to Omaha, NE at the ...
(Date:3/27/2015)... Francisco, CA (PRWEB) March 27, 2015 ... Recovery Yoga for functional fitness athletes. This new program ... a specific protocol for post-workout cool down. This program ... promote breath control and mental focus. , Karen ... “I started practicing yoga long before I started Crossfit® ...
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 SMI ... today announced it has launched the SM1120 MEMS based ... market. The microsensor profile at only 220um x ... maneuverability to reach challenging locations. With industry leading ... hour, the SM1120 provides a broad operating pressure range ...
(Date:3/27/2015)... Operatic contenders and their avid audience will be in ... acclaimed baritone Sherrill Milnes will be overseeing the grand ... Merion in Evanston. The event is the culmination of ... from around the country. “This is a highly-anticipated yearly ... in the country,” said Margaret Gergen, executive director of ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The ... Industry is a professional and in-depth study on ... market with a focus on the Chinese ... of the industry including definitions, classifications, applications and ... provided for both the international and Chinese domestic ...
Breaking Medicine News(10 mins):Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:Endure Yoga Introduces WOD Recovery Yoga 2Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Opera Idol Competition At The Merion In Evanston 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3
... FOR IMMEDIATE RELEASE , A nano-sensor for better ... , In an advance in food safety, researchers ... sensor that detects record low levels of the deadly ... so-called prion diseases. The sensor, which detects binding of ...
... Suracell,s Italian partner, DNA Research, officially launches Suracell ... international markets expected to open soon, SOUTH ... ), the leading provider of genetically directed,personalized age ... in,a series of worldwide partnerships to bring its ...
... Inc. (Nasdaq: PMTI ), a leading researcher ... today announced that,it has entered into a non-exclusive ... PG ) to exploit home-use light-based hair ... retains a non-exclusive,license in the female market to ...
... process helps make sale of long-term care ... insurance simpler for producers, ... Company (NYSE: PTA ) has developed a new streamlined ... qualify for long-term care insurance (LTCi)., Penn Treaty,s LTCi ...
... a New Jolt with Java, BURLINGAME, Calif., ... helps solve people,s everyday problems by,providing reliable "how ... popular bean by providing interesting facts and alternative,uses ... in March.,HowToDoThings.com has created a Caffeine Resource Guide ...
... March 3 New information about food,and diet appears ... a friend,s personal endorsement of a trendy diet, news ... true, and how do you,separate the truth from the ... National Nutrition Month(R), the American Dietetic Association,urges consumers to ...
Cached Medicine News:Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 2Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 3Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 4Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 5Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 6Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 7Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 8Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 9Health News:Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally 2Health News:Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology 2Health News:Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology 3Health News:Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology 4Health News:Penn Treaty Introduces LTCi QuickPass(SM) Program 2Health News:HowToDoThings.com Brews Up New Uses for Coffee That Will Perk You Up in Recognition of March's 'Caffeine Awareness Month' 2Health News:During National Nutrition Month and Beyond, Find the Facts on Nutrition by Focusing on the Science 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: